Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma

British Journal of Cancer

Volumn 106, Issue 2, 2012, Pages 290-296

  Tanaka, N ^a   Miyajima, A ^a   Kikuchi, E ^a   Matsumoto, K ^a,b   Hagiwara, M ^a   Ide, H ^a,c   Kosaka, T ^a   Masuda, T ^c   Nakamura, S ^b   Oya, M ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

^c Saitama Municipal Hospital   (Japan)

Author keywords

angiotensin II receptor blocker; angiotensin II converting enzyme inhibitor; renin angiotensin system; upper tract urothelial carcinoma

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; TRANSITIONAL CELL CARCINOMA; UPPER TRACT UROTHELIAL CARCINOMA;

AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; NEPHRECTOMY; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SURVIVAL RATE; UROLOGIC NEOPLASMS;

EID: 84856438791     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.565     Document Type: Article

References (43)

1. Ager EI, Neo J, Christophil C (2008) The renin-angiotensin system and malignancy. Carcinogenesis 29: 1675-1684
2. Arrieta O, Guevara P, Escobar E, Garc?́a-Navarrete R, Pineda B, Sotelo J (2005) Blockade of angiotensin II type 1 receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92: 1247-1252 (Pubitemid 40604399)
3. Chang CH, Lin JW, Wu LC, Lai MS (2011) Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 29: 3001-3007
4. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA, VATTC Trial (2008) Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 100: 1223-1232
5. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112: 67-75 (Pubitemid 38056377)
6. Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58: 574-580
7. Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Nørgaard M, McLaughlin JK, Friis S (2006) A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 97: 231-236 (Pubitemid 43945753)
8. George AJ, Thomas WG, Hannan RD (2010) The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10: 745-759
9. Grandi AM, Maresca AM (2006) Blockade of the renin-angiotensinaldosterone system: effects on hypertensive target organ damage. Cardiovasc Hematol Agents Med Chem 4: 219-228 (Pubitemid 44027710)
10. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C, Mazzotta A, Manca C, Marsigliante S (2003) Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196: 370-377 (Pubitemid 36775885)
11. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52: 594-601 (Pubitemid 28440164)
12. Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 182: 900-906
13. Holmang S, Johansson SL (2005) Urothelial carcinoma of the upper urinary tract: comparison between the WHO/ISUP 1998 consensus classification and WHO 1999 classification system. Urology 66: 274-278 (Pubitemid 41138081)
14. Jemal A, Siegel R, Xu J, Ward E (2011) Cancer statistics, 2010. CA Cancer J Clin 61: 133-134
15. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, Nguyen G, Wostl W, Maerki HP, Janzer RC, Corvol P, Gasc JM (2004) Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 90: 1059-1068 (Pubitemid 38495829)
16. Kaag MG, O'Malley RL, O'Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, Stifelman MD, Taneja SS, Huang WC (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58: 581-587
17. Khakoo AY, Sidman RL, Pasqualini R, Arap W (2008) Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 68: 9112-9115
18. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H, Tanabe K (2007) Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract. Urology 69: 265-269 (Pubitemid 46274933)
19. Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M (2007) Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 67: 41-49 (Pubitemid 46013466)
20. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M (2006) Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 12: 2888-2893
21. Lane BR, Smith AK, Larson BT, Gong MC, Campbell SC, Raghavan D, Dreicer R, Hansel DE, Stephenson AJ (2010) Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 116: 2967-2973
22. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW (1998) Do inhibitors of angiotensin-1-converting enzyme protect against risk of cancer? Lancet 352: 179-184 (Pubitemid 28327802)
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470 (Pubitemid 29135798)
24. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 98: 1504-1513 (Pubitemid 37151507)
25. Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK (2009) A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 69: 1685-1692
26. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Upper Tract Urothelial Carcinoma Collaboration (2009) Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115: 1224-1233
27. Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116: 3127-3134
28. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, Hayakawa M (2002) Angiotensin II type 1 antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62: 4176-4179 (Pubitemid 34830392)
29. Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S (1998) The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract. BJU Int 82: 494-498 (Pubitemid 28477288)
30. Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y, Mizuno S, Yamamoto K, Arizumi T, Togawa O, Matsubara S, Tsujino T, Tateishi K, Tada M, Omata M, Koike K (2010) Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103: 1644-1648
31. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-S266
32. Opelz G, Döhler B (2011) Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: A Collaborative Transplant Study Report. Am J Transplant 11: 2483-2489
33. Perron L, Bairati I, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15: 535-541 (Pubitemid 39070071)
34. Ronquist G, Rodr?́guez LA, Ruigómez A, Johansson S, Wallander MA, Frithz G, Svärdsudd K (2004) Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 58: 50-56 (Pubitemid 38057988)
35. Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W (2011) European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update. Eur Urol 59: 584-594
36. Shirotake S, Miyajima A, Kosaka T, Tanaka N, Kikuchi E, Mikami S, Okada Y, Oya M (2011a) Regulation of monocyte-chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. Am J Pathol (in press
37. Shirotake S, Miyajima A, Kosaka T, Tanaka N, Maeda T, Kikuchi E, Oya M (2011b) Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology 77(4): 1009.e19-1009.e25
38. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010) Angiotensinreceptor blockade and risk of cancer: meta-analysis of randomized control trials. Lancet Oncol 11: 627-636
39. Tanaka N, Miyajima A, Kosaka T, Shirotake S, Hasegawa M, Kikuchi E, Oya M (2010) Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer. Mol Cancer Ther 9: 2982-2992
40. Tatokoro M, Fujii Y, Kawakami S, Saito K, Koga F, Matsuoka Y, Iimura Y, Masuda H, Kihara K (2011) Phase-II trial of combination treatment of interferon-á, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci 102: 137-143
41. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y (2005) Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 10: 405-410 (Pubitemid 41821524)
42. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E (2009) Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-smallcell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135: 1429-1435
43. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H (2009) Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 51: 315-321